ME02063B - Protutijela koja se vezu na tgf-alfa i epiregulin - Google Patents

Protutijela koja se vezu na tgf-alfa i epiregulin

Info

Publication number
ME02063B
ME02063B MEP-2015-48A MEP201548A ME02063B ME 02063 B ME02063 B ME 02063B ME P201548 A MEP201548 A ME P201548A ME 02063 B ME02063 B ME 02063B
Authority
ME
Montenegro
Prior art keywords
seq
amino acid
antibody according
acid sequence
heavy chain
Prior art date
Application number
MEP-2015-48A
Other languages
English (en)
Unknown language (me)
Inventor
Catherine Brautigam Beidler
Josef George Heuer
Ramona Judita Petrovan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME02063B publication Critical patent/ME02063B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2015-48A 2011-04-06 2012-03-28 Protutijela koja se vezu na tgf-alfa i epiregulin ME02063B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472338P 2011-04-06 2011-04-06
PCT/US2012/030802 WO2012138510A1 (en) 2011-04-06 2012-03-28 Antibodies that bind tgf-alpha and epiregulin
EP12712049.1A EP2694547B1 (en) 2011-04-06 2012-03-28 Antibodies that bind tgf-alpha and epiregulin

Publications (1)

Publication Number Publication Date
ME02063B true ME02063B (me) 2015-05-20

Family

ID=45929050

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-48A ME02063B (me) 2011-04-06 2012-03-28 Protutijela koja se vezu na tgf-alfa i epiregulin

Country Status (26)

Country Link
US (1) US8613921B2 (enExample)
EP (1) EP2694547B1 (enExample)
JP (1) JP2014515743A (enExample)
KR (1) KR101581517B1 (enExample)
CN (1) CN103459423B (enExample)
AR (2) AR085484A1 (enExample)
AU (1) AU2012240508B2 (enExample)
BR (1) BR112013023513A2 (enExample)
CA (1) CA2832256C (enExample)
CY (1) CY1116332T1 (enExample)
DK (1) DK2694547T3 (enExample)
EA (1) EA024921B1 (enExample)
ES (1) ES2539503T3 (enExample)
HR (1) HRP20150468T1 (enExample)
IL (1) IL228101A0 (enExample)
ME (1) ME02063B (enExample)
MX (1) MX2013011596A (enExample)
PL (1) PL2694547T3 (enExample)
PT (1) PT2694547E (enExample)
RS (1) RS54000B1 (enExample)
SG (1) SG193452A1 (enExample)
SI (1) SI2694547T1 (enExample)
TW (1) TWI454481B (enExample)
UA (1) UA110051C2 (enExample)
WO (1) WO2012138510A1 (enExample)
ZA (1) ZA201306813B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물
TWI859538B (zh) 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法
CN119213026A (zh) * 2022-03-04 2024-12-27 耶鲁大学 用于治疗和预防纤维化的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
JP5919593B2 (ja) 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
US20120258109A1 (en) 2012-10-11
CA2832256C (en) 2016-02-09
DK2694547T3 (en) 2015-04-27
EA201370196A1 (ru) 2014-02-28
UA110051C2 (uk) 2015-11-10
RS54000B1 (sr) 2015-10-30
IL228101A0 (en) 2013-09-30
PL2694547T3 (pl) 2015-08-31
JP2014515743A (ja) 2014-07-03
MX2013011596A (es) 2013-12-09
KR101581517B1 (ko) 2015-12-30
PT2694547E (pt) 2015-06-01
EP2694547A1 (en) 2014-02-12
TW201300414A (zh) 2013-01-01
KR20130133274A (ko) 2013-12-06
AU2012240508B2 (en) 2014-10-23
AR085484A1 (es) 2013-10-02
SG193452A1 (en) 2013-10-30
CY1116332T1 (el) 2017-02-08
HRP20150468T1 (hr) 2015-06-05
AU2012240508A1 (en) 2013-08-29
WO2012138510A1 (en) 2012-10-11
ZA201306813B (en) 2015-04-29
SI2694547T1 (sl) 2015-05-29
CN103459423A (zh) 2013-12-18
NZ614198A (en) 2015-09-25
AR123912A2 (es) 2023-01-25
ES2539503T3 (es) 2015-07-01
EA024921B1 (ru) 2016-11-30
US8613921B2 (en) 2013-12-24
TWI454481B (zh) 2014-10-01
BR112013023513A2 (pt) 2016-11-22
CA2832256A1 (en) 2012-10-11
HK1190410A1 (en) 2014-07-04
CN103459423B (zh) 2016-03-02
EP2694547B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
HRP20171992T1 (hr) Protutijela protiv cgrp
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
HRP20160151T1 (hr) PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
HRP20161587T1 (hr) Protutijela protiv bmp-6
JP2015535828A5 (enExample)
JP2013542194A5 (enExample)
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ610734A (en) Human antibodies to the glucagon receptor
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
NZ603529A (en) Antibodies to human gdf8
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
NZ712765A (en) Antibodies that bind csf1r
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ598391A (en) Anti-hepcidin antibodies and uses thereof
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
SI2768859T1 (en) Antagonists of il17c for the treatment of inflammatory disorders